A recent Altarum report finds U.S. health care prices are rising at the fastest growth rate—2.2%—since January 2012, and hospitals are a key price growth driver.

Nurse leaders explain why health care leaders should not overlook nurses in their efforts to "fix the hospital."

House Speaker Paul Ryan's (R-Wis.) announcement that he will not seek re-election in November is raising questions about whether Congress will achieve Ryan's long-sought goal to overhaul federal entitlement programs, such as Medicare and Medicaid.

CVS Health is introducing a new tool, called the "Rx Savings Finder," that will enable pharmacists and customers to better compare drug prices at the pharmacy counter, in an effort to both save customers money on prescriptions and increase drug price transparency.

An HHS Office of Inspector General report finds the federal government recovered $4.20 for every $1 spent through the Health Care Fraud and Abuse Control Program during fiscal years 2015 through 2017.

The Congressional Budget Office report states that "health care costs per beneficiary are projected to grow faster than the economy over the long term, contributing to growth in spending for Medicare and Medicaid in particular."

A Vox analysis digs into the reasons why patients more commonly are seeing "big bills" for "relatively basic medical care."

Bloomberg examines a business strategy allegedly deployed by Todd Smith, chair and CEO of Novum Pharma, and Benjamin Bove, an officer at Novum, at four pharmaceutical companies that seemingly led to major price hikes for some prescription drugs, though Novum says the approach is a "patient-access-centered model" that lowers prices for consumers.

The emergence of urgent care facilities and retail clinics, as well as increasing mergers in the health care industry and the push toward telemedicine, are threatening traditional primary care practices.

Drugmaker AbbVie and Samsung Bioepis reach a settlement agreement that prevents Samsung from selling its biosimilar version of AbbVie's blockbuster drug Humira in the United States until 2023.